ArticleBMC gastroenterology2025
Global burden, trends, and risk factors of early-onset and late-onset colorectal cancer from 1990 to 2021, with projections to 2040: a population-based study.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Biological frailty and chemotherapy dose intensity independently predict survival in older adults with Stage II-III colon cancer.Cancer chemotherapy and pharmacology · 2026Article
- Burden and Forecast of Early-Onset Colorectal Cancer (1990-2038) in Five East Asian Populations: A Systematic Analysis Based on the GBD 2023 Study.Cancer medicine · 2026Article
- Estimating the global macroeconomic impact of colorectal cancer: evidence from Global Burden of Disease 2021 and Value of a Statistical Life Year framework.International journal of surgery (London, England) · 2026Article
- Early-onset digestive system cancers attributable to the GBD composite dietary risk in China, 1990-2023: burden, trends, and projections.Frontiers in medicine · 2026Article
- Global, regional, and national burden of early-onset and late-onset colorectal cancer attributable to high body-mass index from 1990 to 2021: a trend analysis and forecasts up to 2040 based on the global burden of disease study 2021.BMC gastroenterology · 2025Article
- Food Preservatives and the Rising Tide of Early-Onset Colorectal Cancer: Mechanisms, Controversies, and Emerging Innovations.Foods (Basel, Switzerland) · 2025Review
- Article
- Comparing burden of ischemic stroke caused by high low-density lipoprotein cholesterol in global and China: trends and projections.Frontiers in neurology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundEarly-onset colorectal cancer (EOCRC) and late-onset colorectal cancer (LOCRC) are significant public health concerns. There has been limited research comparing EOCRC and LOCRC, particularly regarding their global burden.
methodsThis study used data from the Global Burden of Disease (GBD) 2021 study, covering 204 countries and territories from 1990 to 2021. We analyzed incidence, prevalence, mortality, and disability-adjusted life years (DALY) for EOCRC and LOCRC. Age-standardized rates per 100,000 population were calculated, and trends were assessed using Joinpoint regression analysis. Decomposition analysis identified factors influencing DALY changes, with future burden projections through 2040.
resultsFrom 1990 to 2021, EOCRC cases nearly doubled, rising from 107,309 to 211,890, with the age-standardized incidence rate increasing from 4.58 to 5.15 per 100,000. LOCRC cases more than doubled, from 809,273 to 1,982,252, with the incidence rate rising from 79.67 to 84.38 per 100,000. Despite rising incidence, both EOCRC and LOCRC saw declines in mortality and DALY rates, reflecting improved treatment outcomes. In 2021, East Asia bore the highest burden of both EOCRC and LOCRC. The leading risk factors for both EOCRC and LOCRC were low intake of whole grains, low milk intake, and high red meat intake. Projections suggest incidence and prevalence of both cancers will continue rising through 2040, while mortality and DALY rates will decline, with LOCRC remaining predominant.
conclusionEOCRC incidence is rising rapidly, but LOCRC still accounts for the majority of cases globally. Targeted prevention, better screening, and efficient resource allocation are crucial to addressing this public health challenge.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.